deferoxamine has been researched along with Hepatitis C in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major." | 3.73 | Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006) |
| "We report a case of successful treatment of pulmonary hypertension in a patient with beta-thalassemia major and review the literature on pulmonary hypertension and beta-thalassemia major." | 1.33 | Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. ( Farber, HW; Tam, DH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cerchione, C | 1 |
| Cerciello, G | 1 |
| Avilia, S | 1 |
| Della Pepa, R | 1 |
| Pugliese, N | 1 |
| Picardi, M | 1 |
| Catalano, L | 1 |
| Pane, F | 1 |
| Barbieri, L | 1 |
| Macrì, A | 1 |
| Lupia Palmieri, G | 1 |
| Aurizi, C | 1 |
| Biolcati, G | 1 |
| Hou, WH | 1 |
| Rossi, L | 1 |
| Shan, Y | 1 |
| Zheng, JY | 1 |
| Lambrecht, RW | 1 |
| Bonkovsky, HL | 1 |
| Berdoukas, V | 1 |
| Bohane, T | 1 |
| Tobias, V | 1 |
| De Silva, K | 1 |
| Fraser, I | 1 |
| Aessopos, A | 1 |
| Lindeman, R | 2 |
| Tam, DH | 1 |
| Farber, HW | 1 |
| Wu, SF | 1 |
| Peng, CT | 1 |
| Wu, KH | 1 |
| Tsai, CH | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| De Virgiliis, S | 1 |
| Argiolu, F | 1 |
| Rais, M | 1 |
| Cossu, P | 1 |
| Toccafondi, C | 1 |
| Sanna, G | 1 |
| Cornacchia, G | 1 |
| Nucaro, A | 1 |
| Ferreli, A | 1 |
| Cao, A | 1 |
| Locasciulli, A | 1 |
| Monguzzi, W | 1 |
| Tornotti, G | 1 |
| Bianco, P | 1 |
| Masera, G | 1 |
| Leonardi, S | 1 |
| Musumeci, S | 1 |
| Albo, C | 1 |
| Cabrera, J | 1 |
| Dios, A | 1 |
| Castro, M | 1 |
| Ares, C | 1 |
| Constenla, I | 1 |
| López, D | 1 |
11 other studies available for deferoxamine and Hepatitis C
| Article | Year |
|---|---|
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Topics: Deferasirox; Deferoxamine; Hepatitis C; Humans; Hypertension, Portal; Iron Overload; Liver Cirrhosis | 2018 |
Association between porphyria cutanea tarda and beta-thalassemia major.
Topics: Adult; Anemia; beta-Thalassemia; Chloroquine; Deferoxamine; Female; Hepatitis C; Humans; Iron Overlo | 2009 |
Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells.
Topics: Basic-Leucine Zipper Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Deferoxamin | 2009 |
Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy.
Topics: Adolescent; Adult; Anemia, Diamond-Blackfan; Anemia, Sickle Cell; beta-Thalassemia; Biopsy; Blood Tr | 2005 |
Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.
Topics: Adult; Antihypertensive Agents; beta-Thalassemia; Deferoxamine; Dyspnea; Epoprostenol; Hemosiderosis | 2006 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch | 2006 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
Therapy of HBsAg-negative chronic active hepatitis in transfusion-dependent thalassemia major.
Topics: Aspartate Aminotransferases; Child; Child, Preschool; Deferoxamine; Hepatitis B; Hepatitis B Surface | 1982 |
Hepatitis C virus infection and liver disease in children with thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Combined Modality T | 1993 |
Could chelation therapy with deferoxamine enhance the percentage of responders to interferon therapy in chronic hepatitis C?
Topics: Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferoxamine; Drug Synergism; Ferriti | 1993 |
[Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy | 1995 |